SCHEMBL21611960

SCHEMBL21611960

Nc1cc(SCc2nc3cc(Oc4ccccc4)ccc3[nH]2)cc(C(F)(F)F)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 3/20 0.43
▸ RAB9A P51151 3/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ CYP1A2 P05177 2/20 0.43
▸ CYP3A4 P08684 2/20 0.43
▸ CYP2D6 P10635 2/20 0.43
▸ CYP2C9 P11712 2/20 0.43
▸ CYP2C19 P33261 2/20 0.43
▸ GRIN1 Q05586 7/20 0.41
▸ GRIN2B Q13224 7/20 0.41
▸ LOX P28300 1/20 0.39
▸ LOXL2 Q9Y4K0 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ MAPT P10636 1/20 0.39
▸ POLB P06746 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ PDE10A Q9Y233 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21612005 0.88 RAB9A (0.43) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL21611983 0.85 PDE10A (0.48) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL23611367 0.83 NPC1 (0.39) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL30062605 0.83 NPC1 (0.39) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL21611990 0.82 GRIN1 (0.43) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL30041556 0.82 NPC1 (0.43) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL26260607 0.82 NPC1 (0.43) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL31694532 0.81 SMN1; SMN2 (0.37) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL30060483 0.80 PRMT5 (0.37) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4
SCHEMBL30763506 0.78 GRIN1 (0.40) NPC1RAB9ASMN1; SMN2CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 NPC1 4357/4885RAB9A 722/4885SMN1; SMN2 4555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback